Tempus AI slumps after Spruce Point says it is short on company

** Shares of genetic testing firm Tempus AI TEM slump 16.4% to $55.19 after Spruce Point says it is short on company, citing issues including aggressive accounting, financial engineering and earnings quality

** Investment management firm says co has not shown profits or net positive cash flow in 10 years, and founder has a history of leaving public shareholders with losses or lackluster returns

** Adds that co's revenue as well as deals with AstraZeneca and Pathos AI should be carefully scrutinized

** Co faces up to 50-60% potential downside risk and shares are expected to underperform in both medical diagnostics industry and broader equity market - Spruce Point

** Tempus, backed by Japan's SoftBank 9984, went public last June at a valuation of $6.6 bln

** Six out of 12 analysts rate stock "buy" or higher, six "hold"; Median PT is $65

** With session's moves, TEM up 64.6% YTD